莎普爱思公告称，公司组织开展的立他司特滴眼液III期临床试验于2025年10月23日完成首例受试者入 组。该试验采用多中心、随机、双盲、安慰剂平行对照设计，评价其在中国人群中治疗干眼的有效性和 安全性。截至公告披露日，该项目累计研发投入约1915.15万元。药物从临床试验到投产周期长、环节 多，可能因各种潜在问题终止研发，公司将及时披露进展。 ...

Core Viewpoint - The company received the drug registration certificate for Oubkain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant regulatory approval for a product used in ophthalmic surface anesthesia [1] Company Summary - Shapais (603168) announced on October 24 that it has obtained the drug registration certificate for Oubkain Hydrochloride Eye Drops [1] - The eye drops are intended for use in the field of ophthalmology, specifically for surface anesthesia [1]

Core Insights - On October 16, 17 companies announced a total of 17 stock repurchase updates, indicating a significant activity in the market [1] Group 1: First Disclosure of Repurchase Plans - Three companies disclosed their stock repurchase plans for the first time, with proposed repurchase amounts of up to 400 million yuan, 150 million yuan, and 100 million yuan respectively for Hengmingda, Qizhong Technology, and Kangchen Pharmaceutical [1] Group 2: Approval of Repurchase Plans by Shareholders - Five companies had their repurchase plans approved by shareholder meetings, with the highest proposed repurchase amounts being 150 million yuan for Fenghuo Communication, 70 million yuan for Shaanxi Jinye, and 10 million yuan for Youkede-W [1] Group 3: Progress of Implemented Repurchase Plans - Four companies reported on the progress of their repurchase plans, with the highest repurchase amounts being 37.86 million yuan for Jiuan Medical, 11.19 million yuan for Intercontinental Oil and Gas, and 3.09 million yuan for Jiansheng Group [1] Group 4: Completed Repurchase Plans - Five companies completed their repurchase plans, with the highest completed amounts being 797 million yuan for Zhongwei Co., 200 million yuan for Shuangta Food, and 7.5177 million yuan for Shapais [1]

Core Viewpoint - The company announced the repurchase and cancellation of a total of 1,798,500 restricted stocks due to the departure of four incentive recipients and unmet performance targets for the year 2024 [1][2][4]. Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks were approved during the sixth board meeting on April 28, 2025, due to four incentive recipients leaving the company and not meeting the performance criteria for the second release period of the incentive plan [1][2][3]. Details of the Repurchase - The company will repurchase 186,000 shares from the four departing employees and an additional 1,612,500 shares due to unmet performance targets, totaling 1,798,500 shares [1][2][4]. - The repurchase price is set at 4.18 yuan per share, which may include interest from bank deposits [4]. Impact on Share Structure - Following the repurchase, the total number of shares will decrease from 375,925,005 to 374,126,505 [5]. Compliance and Legal Opinions - The board confirmed that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of incentive recipients or creditors [6][8]. - Legal opinions affirm that the repurchase has obtained necessary approvals and adheres to the relevant regulations, indicating no significant impact on the company's financial performance [8].

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-057 浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励计划 部分限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2、2025 年 4 月 30 日，公司依据相关法律规定就上述回购注销限制性股票 事项履行通知债权人程序，具体内容详见公司于上海证券交易所网站 （www.sse.com.cn）披露的《关于回购注销部分限制性股票减资暨通知债权人的 公告》（公告编号：临 2025-027）。截至本公告披露日公示期均已满 45 天，公 司未收到债权人关于清偿债务或者提供相应担保的要求。 二、 本次限制性股票回购注销情况 （一）本次回购注销限制性股票的原因及依据 回购注销原因： 浙江莎普爱思药业股份有限公司（以下简称"公司"）于2025年4月28日召 开了第六届董事会第八次会议，会议审议通过了《关于回购注销部分限制性股 票的议案》，根据本激励计划的相关规定及公司2023年第一次临时股东大会的 授权，鉴于公司20 ...

上海君澜律师事务所 关于 浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励计划 回购注销部分限制性股票实施相关事项 之 法律意见书 法律意见书 致：浙江莎普爱思药业股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江莎普爱思药业股份有 限公司（以下简称"公司"或"莎普爱思"）的委托，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）及《浙江莎普爱思药业股份有限公司 2023 年股票期权与限制 性股票激励计划》（以下简称"《激励计划》"或"本次激励计划"）的规定，就 莎普爱思本次激励计划回购注销部分激励对象已获授但尚未解除限售的限制性 股票实施相关事项（以下简称"本次回购注销"）出具本法律意见书。 对本法律意见书，本所律师声明如下： 二〇二五年十月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于浙江莎普爱思药业股份有限公司 2023 年股票期权与限制性股票激励计划 回购注销部分限制性股票实施相关事项之 （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执 ...

Core Insights - As of September 29, a total of 100 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Guangming Meat Industry, which has seen net buying for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Shapais, Zhongnan Media, Xintian Green Energy, Xinhua Wenshu, Jiugang Hongxing, Liqun Co., Meikailong, and Fucheng Co. [1]

Core Viewpoint - Shareholder Shanghai Jingxing plans to reduce its stake in Shapuaisi (603168.SH) through a series of transactions scheduled between October 10, 2025, and January 9, 2026 [1] Summary by Category Shareholder Actions - Shanghai Jingxing intends to reduce its holdings by up to 3,759,250 shares through centralized bidding, representing 1.0000% of the company's total share capital [1] - Additionally, the shareholder plans to sell up to 7,518,500 shares via block trading, accounting for 2.0000% of the total share capital [1] - The total reduction in shares will not exceed 11,277,750, which is 3% of the company's total share capital [1]

Summary of Key Points Core Viewpoint - Multiple shareholders of various companies are planning to reduce their holdings, indicating potential shifts in investor sentiment and market dynamics [1]. Group 1: Shareholder Reductions - Changxin Bochuang: Multiple shareholders plan to collectively reduce their holdings by no more than 2.99% [1]. - Fengyuzhu: Shareholder Xin Haoying intends to reduce holdings by no more than 3% [1]. - Panda Dairy: The concerted action of the actual controller's associates plans to reduce holdings by 0.6452% [1]. - Dongfang Communication: Plans to sell no more than 291,100 shares of Changxin Bochuang stock [1]. - Jiaseng Technology: Controlling shareholder Guo Mao intends to reduce holdings by no more than 3% [1]. - Kuai Ke Electronics: Shareholder Chengdu Fuen De Xingyu plans to reduce holdings by a total of 2.0016% [1]. - Suihengyun A: Plans to sell no more than 1% of the total capital stock of Yuexiu Capital [1]. - Shapuaisi: Shareholder Shanghai Jingxing intends to reduce holdings by no more than 3% [1]. - Zhejiang University Network: Plans to sell 48.6 million shares of Wanliyang stock [1]. - Sanmei Co.: Controlling shareholder and actual controller Hu Rongda has cumulatively reduced holdings by 0.9312% [1]. - Compton: Plans to reduce no more than 1% of repurchased shares [1]. - Beifang Co.: Te Wo Shanghai has cumulatively completed a reduction of 3% of the company's shares [1]. - Ha Han Hu Tong: Hengtong Investment has cumulatively reduced holdings by 1.09% [1]. Group 2: Regulatory and Risk Alerts - Fuhuang Steel Structure: The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [1]. - Meichen Technology: The company's stock has been subjected to other risk warnings and is currently suspended from trading [1].

Core Viewpoint - Shanghai Jingxing plans to reduce its shareholding in Shalifei Pharmaceutical Co., Ltd. due to funding needs, with a total reduction of up to 11,277,750 shares, accounting for 3% of the company's total share capital [2][3]. Shareholding Situation - As of September 26, 2025, Shanghai Jingxing holds 12,982,726 unrestricted circulating shares, representing 3.4535% of Shalifei's total share capital [2]. Reduction Plan Details - The reduction will occur in two phases: - Up to 3,759,250 shares through centralized bidding from October 10, 2025, to January 9, 2026, not exceeding 1% of the total share capital [3]. - Up to 7,518,500 shares through block trading during the same period, not exceeding 2% of the total share capital [3]. - The total planned reduction is capped at 11,277,750 shares, which is 3% of the total share capital [3]. Compliance and Commitments - Shanghai Jingxing has made prior commitments regarding shareholding and reduction methods, including a lock-up period of 12 months post-IPO and a commitment to not sell shares below the IPO price during the first two years after the lock-up [7][9]. - The company will adjust the reduction numbers in case of stock changes such as stock dividends or capital increases [6]. Regulatory Compliance - The reduction plan complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines [15].